Is Compounded Semaglutide Safe? The Answer for India in 2026
‘Compounded’ semaglutide is a US idea that does not legally exist in India. What gets sold under that name here is usually unlicensed peptide, and since generic semaglutide now costs about ₹1,300 to ₹1,800 a month, there is no good reason to take the risk.
ALTRcare Medical Team
Clinical Editorial
Short answer: in India, ‘compounded semaglutide’ is not a safe or legal option, because no licensed version of it exists here. What is sold under that label, or as ‘research-grade’ or ‘peptide’ semaglutide, is unlicensed powder or liquid of unknown strength and purity. And since the semaglutide patent expired in March 2026, licensed generic semaglutide costs about ₹1,300 to ₹1,800 a month, so the old price argument for taking the risk is gone.
Key takeaways
- Compounding is a US pharmacy practice that grew during the US semaglutide shortage. The US FDA declared that shortage over in February 2025.
- India has no licensed compounded semaglutide. Peptide powders and ‘research’ vials sold online are unlicensed.
- Licensed generic semaglutide costs about ₹1,290 (vial) to ₹1,800 (pen) a month, with a prescription.
- In April 2026, counterfeit Mounjaro pens made from imported peptide were seized in Haryana. This is what the unlicensed channel looks like.
What ‘compounded’ actually means
In the United States, licensed compounding pharmacies can mix their own versions of a drug when the approved product is in shortage. That is what happened with semaglutide from 2022: telehealth companies sold compounded semaglutide at a fraction of Wegovy's US price. In February 2025 the FDA declared the semaglutide shortage resolved, and compounders had until April and May 2025 to stop making copies. Compounded products were never FDA-approved, and the FDA logged reports of dosing errors with them.
India never had that legal category for semaglutide. Here, a medicine is either approved by CDSCO and made by a licensed manufacturer, or it is not. So when an Instagram page, a Telegram channel or a B2B marketplace offers ‘compounded semaglutide’, it is borrowing an American word for something that, in India, is simply unlicensed.
Why the risk is not worth it
- Unknown strength. Without regulated manufacturing, a vial can contain more or less than the label says. Semaglutide's side effects rise sharply with dose, so an overdose can mean days of vomiting and dehydration.
- Unknown contents. Peptide powders can contain impurities, the wrong peptide, or nothing active at all. Injecting a contaminated product risks infection.
- No cold chain. Semaglutide degrades with heat. A parcel that sat in a delivery van in an Indian summer may not work.
- No doctor. These sellers do not ask for a prescription, which means no one checks whether you should take it, starts you at the right dose, or catches a problem early.
- Not legal. CDSCO's advisory of 10 March 2026 requires a registered doctor's prescription for every GLP-1 sale. Sellers who skip it are breaking the rules, and regulators are acting: Telangana raided 43 pharmacies in August 2026.
What the unlicensed channel looks like
In April 2026, Haryana regulators seized more than 260 counterfeit Mounjaro pens. According to Reuters, the peptide was bought from Alibaba, the labels were printed locally, and the pens were sold on IndiaMART at about 27% below the real price by someone with no pharmaceutical licence. Unlicensed ‘compounded’ semaglutide comes from exactly the same kind of supply chain.
The price argument is gone
Before March 2026, branded semaglutide cost ₹11,000 or more a month in India, which is what made grey-market versions tempting. Today, licensed generics from Natco and Glenmark start at about ₹1,290 to ₹1,760 a month as vials, and Alkem's Semasize pen at about ₹1,800. Novo Nordisk's own Ozempic and Wegovy start at ₹5,660. An unlicensed vial might save a few hundred rupees against a licensed generic. It is not a trade worth making with an injectable medicine.
Choose a licensed path
Take the 2-minute assessment. Our doctors prescribe only licensed, CDSCO-approved semaglutide or tirzepatide, dispensed by a licensed pharmacy and delivered cold.
If you have already used an unlicensed product
Stop using it, keep the packaging, and tell a doctor what you took, how much and for how long. Seek care urgently if you have persistent vomiting, severe abdominal pain, signs of infection at the injection site, or feel faint. A doctor can then restart you on a licensed product at a safe starting dose; do not simply carry on at the dose you were on.
A note on medical advice
This article is educational and not a substitute for medical advice. Only a licensed doctor can decide whether any medication is right for you.
Questions about safety?
Message our care team. We'll explain where our medicine comes from and how it reaches you.
Frequently asked questions
Is compounded semaglutide legal in India?
There is no licensed compounded semaglutide in India. Products sold under that name, or as research-grade or peptide semaglutide, are unlicensed. Every legal GLP-1 sale in India needs a CDSCO-approved product and a registered doctor's prescription.
Is compounded semaglutide safe?
It is not a safe choice in India. Without regulated manufacturing, the strength, purity and storage of the product are unknown, and no doctor is checking your dose or response. Licensed generic semaglutide is now about as cheap, so there is no reason to take the risk.
What is the cheapest licensed semaglutide in India?
Generic vials from Natco and Glenmark start at about ₹1,290 to ₹1,760 a month, and Alkem's Semasize pen at about ₹1,800 a month (launch prices, 2026). All need a prescription.
Is research-grade semaglutide the same as the medicine?
No. ‘Research grade’ peptides are not made or tested to medicine standards and are not meant for injection into people. Counterfeit GLP-1 pens seized in India in 2026 were made from this kind of imported peptide.
Sources
- FDA resolves semaglutide shortage (Alston & Bird)
- India seizes suspected fake Mounjaro pens, says raw materials sourced from Alibaba (Reuters via GDN, 20 April 2026)
- No ads for prescription drugs: panel flags surrogate advertising of GLP-1 obesity drugs (CDSCO advisory of 10 March 2026) (Medical Dialogues, 18 April 2026)
- Telangana DCA raids 43 medical shops over illegal sale of weight-loss drugs (WebIndia123, 15 August 2026)
- Rs 325 to 4,200 a month: Dr Reddy's, Sun Pharma, Glenmark kick off generic semaglutide price war (ThePrint, 21 March 2026)
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed, with no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
